A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer

Clinical trial NCT02426125 · COMPLETED

Trial details

NCT number: NCT02426125
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Urothelial Carcinoma

Start date: 2015-07-13
Primary completion: 2017-04-21
Enrollment: 530

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.